News

AstraZeneca has sealed a five-year research pact with the Harvard Stem Cell Institute (HSCI) to adapt a technique that converts stem cells into human beta cells from for use in the research and development of new diabetes treatments.

Cancer Research UK is partnering with the Engineering and Physical Sciences Research Council to co-fund multidisciplinary research projects from a five-year cash pot totalling £37.5 million.

US regulators have approved Sanofi’s Quadracel vaccine for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in children aged between four and six years old.

Regeneron’s eye jab Eylea (aflibercept) has picked up its fourth vision-related US approval, this time as a treatment for diabetic retinopathy in patients with diabetic macular oedema.

PharmaTimes Digital talks to Chris Boulton, Director of Marketing at AstraZeneca, about diabetes and what the drugs giant is doing to improve treatment outcomes.

Patients with multiple myeloma will not get routine access to Celgene’s Imnovid (pomalidomide) on the National Health Service, cost regulators have now confirmed.

Sun Pharmaceutical has completed its $4-billion merger with Ranbaxy, strengthening its position as the world’s fifth largest specialty generic pharmaceutical company and top-ranking Indian pharma.

UK patients with Mantle Cell Lymphoma have gained access to a new first-line treatment option as Janssen’s Velcade (bortezomib) is now available in the country to treat the condition.

Results of US review into the deaths of two patients taking Eli Lilly’s long-acting antipsychotic Zyprexa Relprevv (olanzapine pamoate) are inconclusive.

Shares in Gilead slipped 2% yesterday on a warning to doctors that the combination of its flagship hepatitis C drugs Harvoni (sofosbuvir/ledipasvir) or Sovaldi (sofosbuvir) with amiodarone may cause potentially fatal irregular heart rhythms.

Merck & Co is pulling the plug on a late-stage trial of its immunotherapy Keytruda (pembrolizumab) in patients with melanoma ahead of schedule, after the drug smashed its targets by beating Bristol-Myers Squibb’s Yervoy (ipilimumab) on survival endpoints.

NHS England is today launching the first ever directory of NHS-endorsed digital mental health services.

Bristol-Myers Squibb has bought itself access to an undisclosed immunoscience programme owned by Danish group Novo Nordisk.

Pfizer and Eli Lilly are getting ready to restart Phase III clinical trials for experimental chronic pain drug tanezumab, after US regulators lifted the partial clinical hold on the programme.

Campaigners are keeping their fingers crossed that, after more than a year of negotiations, the meningitis B vaccine Bexsero could finally become freely available on the UK’s National Health Service.